J&J wraps up potential $1B buyout of Aragon Pharmaceuticals

08/20/2013 | PharmaTimes (U.K.) · San Diego Business Journal

Johnson & Johnson has finalized its purchase of Aragon Pharmaceuticals, which is developing a potential treatment for prostate cancer, for $650 million plus $350 million in potential milestone fees. The acquisition gives J&J access to Aragon's androgen receptor antagonist program, including ARN-509, a drug candidate for castration-resistant prostate cancer. The deal "strengthens our prostate cancer pipeline with a second-generation, potentially best-in-class compound," said Peter Lebowitz, J&J's global therapeutic area head of oncology.

View Full Article in:

PharmaTimes (U.K.) · San Diego Business Journal

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA